Edition:
United Kingdom

Medivir AB (MVIRb.ST)

MVIRb.ST on Stockholm Stock Exchange

35.65SEK
17 Aug 2018
Change (% chg)

-0.10kr (-0.28%)
Prev Close
35.75kr
Open
35.65kr
Day's High
36.00kr
Day's Low
34.75kr
Volume
29,604
Avg. Vol
45,848
52-wk High
81.75kr
52-wk Low
32.10kr

Latest Key Developments (Source: Significant Developments)

Medivir Q2 EBITDA loss roughly unchanged year/year
Wednesday, 25 Jul 2018 

July 25 (Reuters) - Medivir AB ::Q2 NET TURNOVER TOTALED SEK 2.8 MILLION (9.5 M).Q2 LOSS BEFORE INTEREST, TAX, DEPRECIATION AND AMORTIZATION (EBITDA) TOTALED SEK -89.9 MILLION (-90.9 M).  Full Article

Medivir announces positive top-line results from the MIV-711 osteoarthritis phase iia extension study
Thursday, 28 Jun 2018 

June 28 (Reuters) - Medivir AB ::MEDIVIR ANNOUNCES POSITIVE TOP-LINE RESULTS FROM THE MIV-711 OSTEOARTHRITIS PHASE IIA EXTENSION STUDY.  Full Article

Medivir Q1 operating loss narrows
Friday, 27 Apr 2018 

April 27 (Reuters) - Medivir AB ::MEDIVIR Q1 NET TURNOVER TOTALED SEK 4.5 MILLION (17.8 M)OF WHICH SEK 4.5 MILLION (13.7 M) COMPRISED THE FIRST QUARTER’S ROYALTIES.MEDIVIR Q1 LOSS BEFORE INTEREST, TAX, DEPRECIATION AND AMORTIZATION (EBITDA) TOTALED SEK -73.1 MILLION (-80.9 M).  Full Article

Medivir: successful completion of pre-clinical safety studies with MIV-818
Monday, 8 Jan 2018 

Jan 8 (Reuters) - Medivir ::SUCCESSFUL COMPLETION OF PRE-CLINICAL SAFETY STUDIES WITH MIV-818, ENABLING START OF PHASE I CLINICAL STUDIES IN 2018.  Full Article

Medivir proposes directed share issue, calls EGM
Tuesday, 2 Jan 2018 

Jan 2 (Reuters) - Medivir ::THE MEDIVIR BOARD IS SEEKING ISSUE AUTHORIZATIONS TO INCREASE THE COMPANY'S FUNDING FLEXIBILITY AND CALLS FOR AN EXTRAORDINARY GENERAL MEETING.SAYS NOTICE FOR AN EXTRAORDINARY GENERAL MEETING, TO BE HELD ON 26 JANUARY 2018.SAYS ‍PROPOSAL FOR MEETING TO AUTHORIZE BOARD OF DIRECTORS TO RESOLVE ON A DIRECTED SHARE ISSUE OF NOT MORE THAN 20 PERCENT OF NUMBER OF SHARES OF SERIES B​.SAYS ‍IN ADDITION, BOARD PROPOSES THAT MEETING RESOLVES TO AUTHORIZE BOARD OF DIRECTORS TO ISSUE NEW SHARES OF SERIES B WITH PRE-EMPTIVE RIGHTS FOR COMPANY'S SHAREHOLDERS​.SAYS ‍HOLDERS OF MEDIVIR'S SERIES A SHARES HAVE NOTIFIED MEDIVIR THAT THEY ARE POSITIVE TO BOARD OF DIRECTORS' PROPOSALS​.SAYS ‍HOLDERS OF MEDIVIR'S SERIES A SHARES HAVE ALSO DECLARED THAT THEY WILL CONVERT THEIR SERIES A SHARES IN MEDIVIR TO SERIES B SHARES​.SAYS ‍IN ORDER TO ADVANCE MORE RAPIDLY DEVELOPMENT OF COMPANY'S CLINICAL PORTFOLIO, WISHES TO FURTHER INCREASE ITS FLEXIBILITY​.  Full Article

Medivir says Janssen to terminate Simeprevir license by June 2018
Sunday, 10 Dec 2017 

Dec 10 (Reuters) - Medivir Ab ::MEDIVIR ANNOUNCES JANSSEN DECISION TO TERMINATE ITS SIMEPREVIR LICENSE EFFECTIVE JUNE 2018.SAYS JANSSEN PHARMACEUTICALS INC. HAS DECIDED TO TERMINATE THE LICENSE THAT IT HOLDS FOR SIMEPREVIR DUE TO JANSSEN'S ASSESSMENT OF MARKET DEMAND.  Full Article

Medivir announces new cancer project
Wednesday, 8 Nov 2017 

Nov 8 (Reuters) - Medivir Ab :Medivir announces new cancer project, Leukotide, derived from its in-house nucleotide platform.Says Leukotide project is intended to deliver a new drug for the treatment of acute myeloid leukemia (AML) and other hematological malignancies.Says aim of the Leukotide project is to develop a better tolerated and more effective agent that can lead to improved treatment outcomes for patients with AML and other hematological cancers.  Full Article

Medivir Q3 EBITDA loss widens
Thursday, 26 Oct 2017 

Oct 26 (Reuters) - Medivir :Says ‍net turnover for continuing operations totalled SEK 5.1 million (25.7 m), SEK 5.1 million (13.5 m) of which comprised Q3's royalties​.Q3 ‍loss before interest, tax, depreciation and amortisation (EBITDA) totalled SEK -78.3 million (-53.9 m)​.  Full Article

Medivir receives FDA fast track designation for MIV-711 for treatment of OA
Tuesday, 24 Oct 2017 

Oct 24 (Reuters) - Medivir :Medivir receives FDA fast track designation for MIV-711 for the treatment of OA.  Full Article

Medivir reports positive data in remetinostat phase II trial ‍​
Friday, 13 Oct 2017 

Oct 13 (Reuters) - Medivir Ab :Medivir says ‍remetinostat phase ii data demonstrate efficacy on skin lesions, reduction of itching and high tolerability in patients with early-stage mf-type ctcl​.phase II efficacy and safety data in patients with Mycosis Fungoides (MF) type early-stage Cutaneous T-cell Lymphoma (CTCL) demonstrated that remetinostat gel 1%, when applied topically twice daily, reduced the severity of CTCL skin lesions.  Full Article

BRIEF-Medivir Q1 operating loss narrows

* MEDIVIR Q1 NET TURNOVER TOTALED SEK 4.5 MILLION (17.8 M)OF WHICH SEK 4.5 MILLION (13.7 M) COMPRISED THE FIRST QUARTER’S ROYALTIES